RetroSense Therapuetics Logowhite spacerGo to about RetroSenseGo to Investors and Partners pageGo to Product DevelopmentGo to Therapeutics AreasGo to Frequently Asked QuestionsGo to Contact Page
left image bandRight Image band
photoRetroSense Therapeutics develops game-changing gene therapy solutions to restore partial sight for certain eye diseases.
About Us

Management Team

Advisors

Board of Directors

News

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

News & Updates

September 6, 2016: Press Release
Allergan Acquires Gene Therapy Company RetroSense Therapeutics Adding First-In-Class Technology to Company’s Innovative Eye Care Pipeline

September 1, 2016: Article
He may have invented one of neuroscience’s biggest advances. But you’ve never heard of him
STAT, September 2016

September 1, 2016: Press Release
RetroSense Therapeutics Secures Exclusive Worldwide Rights to ReaChR Optogene from the University of California San Diego

August 30, 2016: Press Release
RetroSense Therapeutics Granted Patent on Proprietary Method for Restoring Vision using Optogenetics

August 10, 2016: Press Release
RetroSense Therapeutics Completes Low Dose Cohort in Clinical Trial of Novel Gene Therapy Application of Optogenetics

June 21, 2016: Press Release
RetroSense Therapeutics Selected as one of MIT Technology Review's 50 Smartest Companies of 2016

June 13, 2016: Press Release
RetroSense Therapeutics Selected as a Red Herring Top 100 North America Winner

May 5, 2016: Press Release
RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences

March 21, 2016: Press Release
RetroSense Therapeutics Doses First Patient in Phase I/II Clinical Trial for Lead Compound RST-001

March 18, 2016: Article
Texas Woman Is the First Person to Undergo Optogenetic Therapy
MIT Technology Review, March 2016

March 10, 2016: Press Release
RetroSense Therapeutics to Present at the 8th Ocular Diseases Drug Discovery Conference

February 24, 2016: Article
New Trial Hopes to Restore Sight of Severe-Stage Retinitis Pigmentosa Patients
Optometry Today, February 2016

February 19, 2016: Article
First Human Test of Optogenetics Could Restore Sight to the Blind
Discover Magazine, February 2016

February 19, 2016: Article
In First Human Test of Optogenetics, Doctors Aim to Restore Sight to the Blind
MIT Technology Review, February 2016

January 5, 2016: Article
Revolutionary Neuroscience Technique Slated for Human Clinical Trials
Scientific American, January 2016

November 30, 2015: Press Release
RetroSense Therapeutics to Present at Upcoming Healthcare Conferences

November 18, 2015: Press Release
RetroSense Therapeutics’ Clinical-Stage Development Program to Restore Vision Wins Multiple Awards

November 12, 2015: Press Release
RetroSense Therapeutics Raises $6 million in an Over-Subscribed Series B Financing to Advance Clinical Development of Lead Product RST-001 for Retinitis Pigmentosa

September 10, 2015: Article
A Cure for Blindness Just Might Come From Algae
WIRED, September 2015

August 24, 2015: Press Release
RetroSense Therapeutics’ Lead Gene Therapy Candidate Gets FDA Clearance to Proceed to First-in-Human Clinical Trials

May 15, 2015: Article
How to rewire the eye
Science News, May 2015

April 16, 2015: Article
World’s Largest Gathering of Angels Names RetroSense 2015 Luis Villalobos Award Winner
Angel Capital Association, April 2015

April 7, 2015: Press Release
RetroSense Therapeutics Selected as Finalist for Prestigious Angel Investor Award

January 12, 2015: Press Release
RetroSense Therapeutics to Present at 7th Annual Biotech Showcase Conference

January 8, 2015: Press Release
RetroSense Therapeutics Raises $6 million in Series A Financing to Further Develop Lead Product RST-001 for Retinitis Pigmentosa

November 20, 2014: Press Release
RetroSense Therapeutics Receives Second “Top Project to Watch” Nomination

November 17, 2014: Press Release
RetroSense Therapeutics Signs License Agreement with Massachusetts General Hospital, Expanding Its Optogenetics Intellectual Property Portfolio

October 30, 2014: Press Release
RetroSense Therapeutics Granted Orphan Drug Designation for Lead Product RST-001 for Retinitis Pigmentosa

June 29, 2014: Article
Gene therapy for blindness gets attention of investors
Crain's Detroit Business, June 2014

October 28, 2013: Press Release
RetroSense Therapeutics Selected by Windhover as a "Top Project to Watch: Most Licensable Product"

March 27, 2013: Press Release
RetroSense Therapeutics Announces Exclusive Option to Intellectual Property Covering Vision Augmentation from Massachusetts General Hospital

March 5, 2013: Press Release
RetroSense Therapeutics Announces Notice of Allowance for New U.S. Patent Application Broadly Covering Optogenetic Approaches to Vision Restoration

February 18, 2013: Article
How Neuroscience Will Fight Five Age-Old Afflictions
Popular Science, March 2013

October 4, 2012: Press Release
RetroSense Therapeutics Welcomes Dr. Steven Bramer as Chief Development Officer

August 28, 2012: Article
Company Aims to Cure Blindness with Optogenetics
Technology Review (MIT), August 2012

June 6, 2012: Article
Optogenetics Workshop Sheds Light on Opportunities for Restoring Vision

May 24, 2012: Press Release
RetroSense Therapeutics Completes pre-IND Meeting for RST-001

April 19, 2012: Press Release
RetroSense Welcomes Dr. Peter Francis as Clinical Director

April 19, 2012: Article
Novel Optogenetic Therapy May Restore Vision After Retinal Degeneration
Retina Today, April 2012

March 2012: Press Release
RetroSense Therapeutics receives grant from the Foundation Fighting Blindness for Wayne State University-licensed technology

October 2011: Press Release
RetroSense Therapeutics Announces License Agreement With Wayne State University for Breakthrough Approaches to Vision Restoration.
     Read at Wayne State site
     Read at PR Newswire

Font Size